Literature DB >> 28735353

Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.

Sujan T Reddy1, T C Cossey2, Sean I Savitz2, James C Grotta3.   

Abstract

PURPOSE OF REVIEW: An 80-year-old man presents with an acute right hemiparesis and National Institutes of Health Stroke Scale (NIHSS) of 25, 14 h after taking dabigatran. Activated partial thromboplastin time (aPTT) is 42.8 s. Arteriogram demonstrates left internal carotid artery thrombosis. What is the appropriate management of this patient with acute ischemic stroke while on a NOAC? RECENT
FINDINGS: Idarucizumab is a reversal agent approved for dabigatran, and two more reversal agents, andexanet alfa and aripazine, are currently in development for NOACs. In this article, we review currently available NOACs, their laboratory monitoring, and reversal agents.

Entities:  

Keywords:  Antidote for NOAC; NOAC; NVAF; Newer oral anticoagulants; Reversal agents; Stroke

Mesh:

Substances:

Year:  2017        PMID: 28735353     DOI: 10.1007/s11910-017-0774-6

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  58 in total

1.  Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study.

Authors:  Maurizio Paciaroni; Giancarlo Agnelli; Valeria Caso; Georgios Tsivgoulis; Karen L Furie; Prasanna Tadi; Cecilia Becattini; Nicola Falocci; Marialuisa Zedde; Azmil H Abdul-Rahim; Kennedy R Lees; Andrea Alberti; Michele Venti; Monica Acciarresi; Cataldo D'Amore; Maria Giulia Mosconi; Ludovica Anna Cimini; Antonio Procopio; Paolo Bovi; Monica Carletti; Alberto Rigatelli; Manuel Cappellari; Jukka Putaala; Liisa Tomppo; Turgut Tatlisumak; Fabio Bandini; Simona Marcheselli; Alessandro Pezzini; Loris Poli; Alessandro Padovani; Luca Masotti; Vieri Vannucchi; Sung-Il Sohn; Gianni Lorenzini; Rossana Tassi; Francesca Guideri; Maurizio Acampa; Giuseppe Martini; George Ntaios; Efstathia Karagkiozi; George Athanasakis; Kostantinos Makaritsis; Kostantinos Vadikolias; Chrysoula Liantinioti; Maria Chondrogianni; Nicola Mumoli; Domenico Consoli; Franco Galati; Simona Sacco; Antonio Carolei; Cindy Tiseo; Francesco Corea; Walter Ageno; Marta Bellesini; Giovanna Colombo; Giorgio Silvestrelli; Alfonso Ciccone; Umberto Scoditti; Licia Denti; Michelangelo Mancuso; Miriam Maccarrone; Giovanni Orlandi; Nicola Giannini; Gino Gialdini; Tiziana Tassinari; Maria Luisa De Lodovici; Giorgio Bono; Christina Rueckert; Antonio Baldi; Sebastiano D'Anna; Danilo Toni; Federica Letteri; Martina Giuntini; Enrico Maria Lotti; Yuriy Flomin; Alessio Pieroni; Odysseas Kargiotis; Theodore Karapanayiotides; Serena Monaco; Mario Maimone Baronello; Laszló Csiba; Lilla Szabó; Alberto Chiti; Elisa Giorli; Massimo Del Sette; Davide Imberti; Dorjan Zabzuni; Boris Doronin; Vera Volodina; Patrik Michel; Peter Vanacker; Kristian Barlinn; Lars-Peder Pallesen; Jessica Kepplinger; Ulf Bodechtel; Johannes Gerber; Dirk Deleu; Gayane Melikyan; Faisal Ibrahim; Naveed Akhtar; Vanessa Gourbali; Shadi Yaghi
Journal:  Stroke       Date:  2017-02-09       Impact factor: 7.914

2.  Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.

Authors:  Benjamin A Steinberg; Peter Shrader; Laine Thomas; Jack Ansell; Gregg C Fonarow; Bernard J Gersh; Peter R Kowey; Kenneth W Mahaffey; Gerald Naccarelli; James Reiffel; Daniel E Singer; Eric D Peterson; Jonathan P Piccini
Journal:  J Am Coll Cardiol       Date:  2016-12-20       Impact factor: 24.094

3.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld
Journal:  Eur J Cardiothorac Surg       Date:  2016-09-23       Impact factor: 4.191

4.  Clinical and radiological course of intracerebral haemorrhage associated with the new non-vitamin K anticoagulants.

Authors:  Christian von der Brelie; Alexandros Doukas; Rebecca Naumann; Astrid Dempfle; Naomi Larsen; Michael Synowitz; Olav Jansen; Maximilian Mehdorn; Senol Jadik
Journal:  Acta Neurochir (Wien)       Date:  2016-11-21       Impact factor: 2.216

5.  How I use anticoagulation in atrial fibrillation.

Authors:  Benjamin A Steinberg
Journal:  Blood       Date:  2016-10-25       Impact factor: 22.113

6.  Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.

Authors:  Robert G Hart; Hans-Christoph Diener; Sean Yang; Stuart J Connolly; Lars Wallentin; Paul A Reilly; Michael D Ezekowitz; Salim Yusuf
Journal:  Stroke       Date:  2012-04-05       Impact factor: 7.914

7.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Truman J Milling; John W Eikelboom; C Michael Gibson; John T Curnutte; Alex Gold; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Shelly Goodman; Janet Leeds; Brian L Wiens; Deborah M Siegal; Elena Zotova; Brandi Meeks; Juliet Nakamya; W Ting Lim; Mark Crowther
Journal:  N Engl J Med       Date:  2016-08-30       Impact factor: 91.245

8.  Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.

Authors:  Ajay K Kakkar; Iris Mueller; Jean-Pierre Bassand; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Werner Hacke; Gregory Y H Lip; Lorenzo G Mantovani; Alexander G G Turpie; Martin van Eickels; Frank Misselwitz; Sophie Rushton-Smith; Gloria Kayani; Peter Wilkinson; Freek W A Verheugt
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

9.  Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs.

Authors:  Raul Altman; Claudio Daniel Gonzalez
Journal:  Thromb J       Date:  2014-03-21

10.  Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry.

Authors:  Nina Vene; Alenka Mavri; Mirjam Gubenšek; Gregor Tratar; Tjaša Vižintin Cuderman; Maja Pohar Perme; Aleš Blinc
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

View more
  1 in total

Review 1.  Reversal Strategies for Intracranial Hemorrhage Related to Direct Oral Anticoagulant Medications.

Authors:  Alok Dabi; Aristides P Koutrouvelis
Journal:  Crit Care Res Pract       Date:  2018-07-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.